HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today commented on inaccurate and misleading information about its generic product pipeline that appears in several financial articles circulated on numerous financial websites. The articles incorrectly state the Company has figured out a way to make a generic version of Lipitor®. The Company stated that while it currently has 98 exciting generic product opportunities in its pipeline of which 36 are already filed at the FDA, it has never filed an Abbreviated New Drug Application for a generic version of Lipitor®. In addition, the Company has no agreement with any company to produce or market a generic version of Lipitor®.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.
CONTACT:
Impax Laboratories, Inc.
Mark Donohue
Sr. Director, Investor Relations and Corporate Communications
215-933-3526
www.impaxlabs.com
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical
MEDIA:
| Logo |